Older Version of Heparin Cheaper, Effective

NOVEMBER 01, 2006
Susan Farley

In the prevention of blood clots in the legs and lungs, a recent study shows that the older, cheaper version of heparin, when given subcutaneously, provides results as good as the newer, more expensive version that is administered through intravenous infusion. Investigators report that the additional cost benefit of the older version is that it does not require continuous monitoring through the activated partial thromboplastin time (APTT) test. The study included 697 patients susceptible to thromboembolism treated at 6 medical centers in Canada and New Zealand. All patients received heparin (Coumadin) as treatment; 70% of patients were treated as outpatients. Among those patients given the older version of heparin, 3.8% had recurrent clots, compared with 3.4% of patients receiving the newer version of low-molecular-weight fractionated heparin. The necessity of APTT testing required with the intravenous infusion increases the cost of treatment considerably: a 6-day course of the subcutaneous, older version of heparin would cost $37, compared with $712 for the newer, fractionated heparin. The results were published in the August 23/30, 2006, issue of the Journal of the American Medical Association.

Ms. Farley is a freelance medical writer based in Wakefield, RI.


The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.



Conference Coverage
News from the year's biggest meetings

Pharmacist Education
Clinical features with downloadable PDFs


Personalize the information you receive by selecting targeted content and special offers.